ARWR - アロ―ヘッド・リサ―チ （Arrowhead Pharmaceuticals Inc.）ARWRのニュース
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics 2022/05/26 11:30:00 Kwhen Finance
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics 2022/05/26 11:30:00 Arrowhead Pharmaceuticals
PASADENA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its
Arrowhead Pharma down 12% despite quarterly beats, swing to net gain (NASDAQ:ARWR) 2022/05/11 18:12:35 Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) is down 12% in Wednesday afternoon trading despite reporting Q1 2022 results after the closing bell Tuesday that beat on the top and bottom…
Benzinga''s Top Ratings Upgrades, Downgrades For May 11, 2022 2022/05/11 14:02:45 Benzinga
Upgrades According to Roth Capital, the prior rating for Hecla Mining Co (NYSE: HL ) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $9.44 and a 52-week-low of $4.28. At the end of the last trading period, Hecla Mining closed at $4.36. According to Zelman, the prior rating for The AZEK Co Inc (NYSE: AZEK ) was changed from Hold to Buy. For the second quarter, AZEK Co had an EPS of $0.33, compared to year-ago quarter EPS of $0.25. At the moment, the stock has a 52-week-high of $50.65 and a 52-week-low of $17.00. AZEK Co closed at $17.33 at the end of the last trading period. According to Maxim Group, the prior rating for Celsius Holdings Inc (NASDAQ: CELH ) was changed from Hold to Buy. In the first quarter, Celsius Holdings showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $110.22 and a 52-week-low of $38.31. At the end of the last trading period, Celsius Holdings closed at $41.31.
Here''s Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today 2021/07/02 16:18:27 The Motley Fool
A paused clinical trial with an important asset wasn''t what investors wanted to hear today.
Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatment 2021/07/02 14:29:16 The Street
Arrowhead''s move comes after a toxicology study in rats contained unexpected signals of local lung inflammation, the company says.
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis 2021/07/02 14:24:12 Endpoints News
Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its RNAi drugs, Arrowhead faces animal tox issues again in what could be
Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet 2021/07/02 12:18:00 Benzinga
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to
B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals By Investing.com 2021/03/18 15:05:10 Investing.com
B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals
Hereditary Angioedema Market to Demonstrates a Spectacular Growth with CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies 2021/03/18 06:37:38 OpenPR
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia 2021/03/01 12:30:00 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
Global Hepatitis B Virus (HBV) Market Report 2021-2030 Featuring Key players | Johnson & Johnson, Merck and Co, Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals, Arbutus Pharma 2021/02/24 21:15:00 PR Newswire
DUBLIN, Feb. 24, 2021 /PRNewswire/ -- The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has been added to ResearchAndMarkets.com's offering. The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030,…